ylliX - Online Advertising Network
Company Ticker News

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In 33 patients enrolled in the trial, the relapse-free survival (RFS) at 1-year post-transplant was 58%, and the median RFS was 12.1 months.

...read full article on Benzinga

ylliX - Online Advertising Network